XDR Tuberculosis News and Research

RSS
Extensively drug-resistant tuberculosis (XDR TB) is a relatively rare type of multidrug-resistant tuberculosis (MDR TB). It is resistant to almost all drugs used to treat TB, including the two best first-line drugs: isoniazid and rifampin. XDR TB is also resistant to the best second-line medications: fluoroquinolones and at least one of three injectable drugs (i.e., amikacin, kanamycin, or capreomycin).

Because XDR TB is resistant to the most powerful first-line and second-line drugs, patients are left with treatment options that are much less effective and often have worse treatment outcomes.

XDR TB is of special concern for persons with HIV infection or other conditions that can weaken the immune system. These persons are more likely to develop TB disease once they are infected, and also have a higher risk of death once they develop TB disease.

The risk of acquiring XDR TB in the United States appears to be relatively low. However, it is important to acknowledge the ease at which TB can spread. As long as XDR TB exists, the United States is at risk and must address the threat.
Report: Global increase in drug-resistant TB threatens to ruin efforts to eradicate the disease

Report: Global increase in drug-resistant TB threatens to ruin efforts to eradicate the disease

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

MDR-TB, XDR-TB more widespread than previously believed, study shows

MDR-TB, XDR-TB more widespread than previously believed, study shows

Drug-resistant tuberculosis levels described as alarming by international study

Drug-resistant tuberculosis levels described as alarming by international study

Totally drug resistant Tuberculosis hits India

Totally drug resistant Tuberculosis hits India

Plans to tackle drug resistant tuberculosis

Plans to tackle drug resistant tuberculosis

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

Pilot program to fight drug-resistant tuberculosis in South African communities examined by New York Times

Pilot program to fight drug-resistant tuberculosis in South African communities examined by New York Times

Urgent need for stringent TB screening policies among South African healthcare workers

Urgent need for stringent TB screening policies among South African healthcare workers

AP/Google.com examines efforts to address drug-resistant tuberculosis in China, other countries

AP/Google.com examines efforts to address drug-resistant tuberculosis in China, other countries

Slow-growing tuberculosis bacteria point the way to new drug development

Slow-growing tuberculosis bacteria point the way to new drug development

About 25% of tuberculosis deaths occur among HIV-positive people

About 25% of tuberculosis deaths occur among HIV-positive people

Drug-resistant tuberculosis increasing among U.S. immigrant populations

Drug-resistant tuberculosis increasing among U.S. immigrant populations

New tuberculosis test dramatically cuts diagnosis time

New tuberculosis test dramatically cuts diagnosis time

Drug combo shows potential for treating extensively drug resistant tuberculosis

Drug combo shows potential for treating extensively drug resistant tuberculosis

XDR-TB declining in the U.S.

XDR-TB declining in the U.S.

Tuberculosis researchers discuss challenges, next steps for addressing XDR-TB, MDR-TB in Africa at TB symposium

Tuberculosis researchers discuss challenges, next steps for addressing XDR-TB, MDR-TB in Africa at TB symposium

Aggressive treatment regimens can successfully treat XDR-TB, MDR-TB

Aggressive treatment regimens can successfully treat XDR-TB, MDR-TB

Potential treatment for TB solves puzzle

Potential treatment for TB solves puzzle

New target for the potential treatment of tuberculosis

New target for the potential treatment of tuberculosis